|
1
|
Campbell IW: Metformin - life begins at
50: A symposium held on the occasion of the 43rd Annual Meeting of
the European Association for the Study of Diabetes, Amsterdam, The
Netherlands, September 2007. (Meeting Report). Br J Diabet Vasc
Dis. 7:247–252. 2007. View Article : Google Scholar
|
|
2
|
Li J, Deng J, Sheng W and Zuo Z: Metformin
attenuates Alzheimer’s disease-like neuropathology in obese,
leptin-resistant mice. Pharmacol Biochem Behav. 101:564–574.
2012.PubMed/NCBI
|
|
3
|
Wahlqvist ML, Lee MS, Hsu CC, Chuang SY,
Lee JT and Tsai HN: Metformin-inclusive sulfonylurea therapy
reduces the risk of Parkinson’s disease occurring with Type 2
diabetes in a Taiwanese population cohort. Parkinsonism Relat
Disord. 18:753–758. 2012.PubMed/NCBI
|
|
4
|
Gallagher EJ and LeRoith D: Diabetes,
cancer, and metformin: connections of metabolism and cell
proliferation. Ann NY Acad Sci. 1243:54–68. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Libby G, Donnelly LA, Donnan PT, Alessi
DR, Morris AD and Evans JM: New users of metformin are at low risk
of incident cancer: a cohort study among people with type 2
diabetes. Diabetes Care. 32:1620–1625. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Evans JM, Donnelly LA, Emslie-Smith AM,
Alessi DR and Morris AD: Metformin and reduced risk of cancer in
diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhuang Y and Miskimins WK: Metformin
induces both caspase-dependent and poly(ADP-ribose)
polymerase-dependent cell death in breast cancer cells. Mol Cancer
Res. 9:603–615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Will MA, Palaniappan M, Peegel H,
Kayampilly P and Menon KM: Metformin: direct inhibition of rat
ovarian theca-interstitial cell proliferation. Fertil Steril.
98:207–214. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Colquhoun AJ, Venier NA, Vandersluis AD,
Besla R, Sugar LM, Kiss A, Fleshner NE, Pollak M, Klotz LH and
Venkateswaran V: Metformin enhances the antiproliferative and
apoptotic effect of bicalutamide in prostate cancer. Prostate
Cancer Prostatic Dis. 15:346–352. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou G, Myers R, Li Y, Chen Y, Shen X,
Fenyk-Melody J, et al: Role of AMP-activated protein kinase in
mechanism of metformin action. J Clin Invest. 108:1167–1174. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shaw RJ, Lamia KA, Vasquez D, Koo SH,
Bardeesy N, Depinho RA, Montminy M and Cantley LC: The kinase LKB1
mediates glucose homeostasis in liver and therapeutic effects of
metformin. Science. 310:1642–1646. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ben Sahra I, Regazzetti C, Robert G,
Laurent K, Le Marchand-Brustel Y, Auberger P, Tanti JF,
Giorgetti-Peraldi S and Bost F: Metformin, independent of AMPK,
induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer
Res. 71:4366–4372. 2011.PubMed/NCBI
|
|
13
|
Zhuang Y and Miskimins WK: Cell cycle
arrest in Metformin treated breast cancer cells involves activation
of AMPK, downregulation of cyclin D1, and requires p27Kip1 or
p21Cip1. J Mol Signal. 3:182008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Peacock KH and Lesser GJ: Current
therapeutic approaches in patients with brain metastases. Curr
Treat Options Oncol. 7:479–489. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou J, Atsina KB, Himes BT, Strohbehn GW
and Saltzman WM: Novel delivery strategies for glioblastoma. Cancer
J. 18:89–99. 2012. View Article : Google Scholar
|
|
16
|
Krakstad C and Chekenya M: Survival
signalling and apoptosis resistance in glioblastomas: opportunities
for targeted therapeutics. Mol Cancer. 9:1352010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Łabuzek K, Suchy D, Gabryel B, Bielecka A,
Liber S and Okopień B: Quantification of metformin by the HPLC
method in brain regions, cerebrospinal fluid and plasma of rats
treated with lipopolysaccharide. Pharmacol Rep. 62:956–965.
2010.PubMed/NCBI
|
|
18
|
Ferreira CG, Epping M, Kruyt FA and
Giaccone G: Apoptosis: target of cancer therapy. Clin Cancer Res.
8:2024–2034. 2002.PubMed/NCBI
|
|
19
|
Twentyman PR and Luscombe M: A study of
some variables in a tetrazolium dye (MTT) based assay for cell
growth and chemosensitivity. Br J Cancer. 56:279–285. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Muppidi J, Porter M and Siegel RM:
Measurement of apoptosis and other forms of cell death. Curr Protoc
Immunol. Chapter 3(Unit 3): 172004.PubMed/NCBI
|
|
21
|
Ben Sahra I, Le Marchand-Brustel Y, Tanti
JF and Bost F: Metformin in cancer therapy: a new perspective for
an old antidiabetic drug? Mol Cancer Ther. 9:1092–1099. 2010.
|
|
22
|
Jalving M, Gietema JA, Lefrandt JD, de
Jong S, Reyners AK, Gans RO and de Vries EG: Metformin: taking away
the candy for cancer? Eur J Cancer. 46:2369–2380. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Iliopoulos D, Hirsch HA and Struhl K:
Metformin decreases the dose of chemotherapy for prolonging tumor
remission in mouse xenografts involving multiple cancer cell types.
Cancer Res. 71:3196–3201. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Janjetovic K, Vucicevic L, Misirkic M,
Vilimanovich U, Tovilovic G, Zogovic N, et al: Metformin reduces
cisplatin-mediated apoptotic death of cancer cells through
AMPK-independent activation of AKT. Eur J Pharmacol. 651:41–50.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rattan R, Graham RP, Maguire JL, Giri S
and Shridhar V: Metformin suppresses ovarian cancer growth and
metastasis with enhancement of cisplatin cytotoxicity in vivo.
Neoplasia. 13:483–491. 2011.PubMed/NCBI
|
|
26
|
Isakovic A, Harhaji L, Stevanovic D,
Markovic Z, Sumarac-Dumanovic M, Starcevic V, Micic D and Trajkovic
V: Dual antiglioma action of metformin: cell cycle arrest and
mitochondria-dependent apoptosis. Cell Mol Life Sci. 64:1290–1302.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vucicevic L, Misirkic M, Janjetovic K,
Harhaji-Trajkovic L, Prica M, Stevanovic D, Isenovic E, Sudar E,
Sumarac-Dumanovic M, Micic D and Trajkovic V: AMP-activated protein
kinase-dependent and -independent mechanisms underlying in vitro
antiglioma action of compound C. Biochem Pharmacol. 77:1684–1693.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kraskstad C and Chekenya M: Survival
signalling and apoptosis resistance in glioblastomas: opportunities
for targeted therapeutics. Mol Cancer. 9:1352010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mao H, Lebrun DG, Yang J, Zhu VF and Li M:
Deregulated signaling pathways in glioblastoma multiforme:
molecular mechanisms and therapeutic targets. Cancer Invest.
30:48–56. 2012. View Article : Google Scholar : PubMed/NCBI
|
